Eli Lilly and Company (LLY) on Friday said it has agreed to acquire Adverum Biotechnologies, Inc. (ADVM) in a transaction valued at up to $12.47 per share.
Under the terms of the agreement, Lilly will launch a tender offer to purchase all outstanding Adverum shares for $3.56 per share in cash, plus one contingent value right (CVR) per share. Each CVR will entitle holders to receive up to an additional $8.91 in cash, contingent upon the achievement of two specified milestones.
Adverum shareholders will receive $1.78 per CVR if Ixo-vec, the company's lead gene therapy candidate for wet age-related macular degeneration (wAMD), secures U.S. regulatory approval within seven years of the deal's closing. They will be eligible for a further $7.13 per CVR if Ixo-vec achieves annual global net sales exceeding $1 billion within ten years of closing.
Ixo-vec is a single-administration intravitreal gene therapy currently being evaluated in a Phase 3 trial, known as ARTEMIS, for patients with wAMD.
The transaction is expected to close in the fourth quarter of 2025.
Adverum shares jumped over 20% in premarket trading, after closing Thursday at $4.18.
Lilly's shares closed at $821.04, up 1.06% on Thursday.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.